International Flavors & Fragrances Inc. reports developments across flavors, fragrances, food ingredients, health and biosciences for customers in food, beverage, personal care, home care, pet health and related markets. News frequently covers ingredient innovation, application labs and natural-extraction capabilities, including vanilla work in Madagascar and LMR Naturals in perfumery, cosmetics and flavors.
Company updates also address probiotics and bioscience products such as HOWARU Pet and PureStrong, nutrition claims tied to soy protein, quarterly earnings releases, dividends, and other capital or financial disclosures.
IFF (NYSE: IFF) published Dear Dairy: The Life Stages Guide, a resource examining changing consumer priorities for dairy products throughout life. Drawing on Panoptic, its proprietary trend and foresight capability, the guide covers childhood, adolescence and young adulthood, adult routines, and healthy aging.
IFF identifies opportunities to align dairy products with each stage, from taste and nutrition for children to convenience for adults and nutrition supporting healthy aging. The guide includes four product concepts illustrating applications of its flavor, formulation and related technologies. It is intended for food and supplement producers, not final consumers.
IFF (NYSE: IFF) introduced AQUASCENT™, a vegan, water-based carrier for fine fragrance, as part of its Science of Performance platform.
IFF says the technology maintains visual clarity while supporting fragrance loads from 10% to up to 25%, compared with up to 15% for most comparable systems. The proprietary formula uses biodegradable materials and has no intentionally added ethanol, preservatives or silicone. It can be supplied as a concentrate, allowing brands to add water during final production rather than ship it within the formula.
IFF (IFF) launched Omni-Bos™ PHY, a novel phytase enzyme developed specifically for dairy cattle to improve nutrient utilization and feed efficiency by unlocking nutrients already present in feed. The product will first be available in the Middle East, Africa and Asia-Pacific regions.
Omni-Bos™ PHY is designed to withstand ruminant digestive conditions and help cows better use protein, phosphorus and minerals in existing feed ingredients. In one study, it reduced undegraded phytate in the abomasum by approximately 70% compared with a control diet. Additional trials in lactating cows showed improved phosphorus and phytate digestibility, reduced nitrogen and phosphorus excretion, and increased digestibility of nutrients such as crude protein and calcium.
IFF (NYSE: IFF) released a new report, “Inside the India GLP-1 Consumer Journey,” analyzing how GLP-1 use is reshaping food behaviors among consumers in Delhi, Mumbai and Bengaluru. The study finds users are eating smaller portions while becoming more deliberate about nutrition, taste, ingredient quality and satisfaction.
Key data points include 74% reading food labels more carefully, 90% noticing changes in how food tastes or feels, 50% preferring softer textures, and 74% viewing hydration as a daily wellness goal, with many choosing coconut water and electrolyte-based beverages.
IFF (NYSE: IFF) announced that Chief Executive Officer Erik Fyrwald will take part in a fireside chat at the Barclays Global Consumer Conference/b) on . The discussion will be available via live webcast and subsequent replay on IFF’s investor relations website.
IFF (NYSE: IFF) reported second quarter 2026 results on a continuing-operations basis, with net sales of $1.95 billion, up 2% year over year, and adjusted operating EBITDA of $408 million, implying a 20.9% margin and 6% comparable currency-neutral EBITDA growth. Adjusted EPS excluding amortization was $0.82. All three core segments grew on a comparable currency-neutral basis: Taste sales +4%, Health & Biosciences +5%, and Scent +8%.
For the first six months, sales were $3.86 billion and adjusted operating EBITDA $841 million. Free cash flow reached $378 million, up $284 million year over year. IFF highlighted net debt to credit-adjusted EBITDA of 2.5x.
The company detailed its portfolio reshaping, including the previously announced sale of its Food Ingredients disposal group to CVC Capital Partners for approximately $3.8 billion in expected net cash proceeds, with closing targeted by the end of Q2 2027 and IFF retaining about a 10% minority stake. IFF expects about $100 million of stranded costs after closing and plans to eliminate roughly two thirds within one year and substantially all within two years.
IFF’s board approved an enhanced $2.5 billion share repurchase authorization, including about $400 million remaining from a prior program. This includes a $500 million accelerated share repurchase in the second half of 2026 and an additional $2.0 billion in buybacks expected after the Food Ingredients transaction closes, with completion targeted by the end of 2027. IFF intends to use more than $1 billion of net divestiture proceeds to reduce debt.
On a continuing-operations basis, IFF issued 2026 guidance for sales of $7.4–$7.6 billion and adjusted operating EBITDA of $1.53–$1.60 billion, excluding about $3.2 billion of sales and $520 million of adjusted EBITDA from discontinued operations. The company expects comparable currency-neutral sales growth of 2%–4% and comparable currency-neutral adjusted operating EBITDA growth of 4%–8%, with foreign exchange projected to contribute about 1 percentage point to sales growth and 2 percentage points to adjusted EBITDA growth in 2026.
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share on its common stock. The dividend is payable on October 9, 2026 to shareholders of record as of September 18, 2026. The company describes itself as a global leader in flavors, fragrances, and health and biosciences.
SuanNutra, a Carbyne Equity Partners portfolio company, has signed an agreement to acquire a portfolio of specialty natural ingredients businesses from IFF (NYSE: IFF). The acquired operations will be merged with SuanNutra to form an enlarged global group focused on science-backed natural ingredients.
The combined business will offer clinically supported branded ingredients, botanical extraction at source, fermented vitamins and minerals, and plant-derived natural colours, antioxidants and flavours. The group will have around 700 employees, serving more than 1,200 customers in over 60 countries, with manufacturing across Spain, Slovenia, Peru and the United States. Completion is targeted by the end of 2026, subject to regulatory clearances and customary conditions.
IFF (NYSE: IFF) announced an agreement to sell its portfolio of botanical extracts, vitamins and minerals, and food enhancement activities, including natural colors, antioxidants and certain localized flavor activities in Peru, to SuanNutra, a Carbyne Equity Partners portfolio company.
The portfolio generated approximately $170 million in 2025 revenue, employs about 600 people, and operates across five manufacturing facilities in Europe, the United States and Latin America. Financial terms were not disclosed. The companies expect to close the transaction by the end of 2026, subject to customary regulatory clearances and consultation requirements. IFF said the divestiture supports its focus on its core Taste, Scent and Health & Biosciences businesses.
IFF (NYSE:IFF) will release its second quarter 2026 earnings results after market close on Tuesday, August 4, 2026. Management will host a live webcast on Wednesday, August 5, 2026 at 9:00 a.m. ET to discuss results and outlook with investors.
The webcast, slides and replay will be available on ir.iff.com.